A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT signal pathway in prostate cancer

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Su, Bing ^a,b   Gao, Lingqiu ^b   Baranowski, Catherine ^b   Gillard, Bryan ^b   Wang, Jianmin ^b   Ransom, Ryan ^b   Ko, Hyun Kyung ^c   Gelman, Irwin H ^b  

^a Biomedical Research Institute   (China)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR FOXO4; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; FOXO4 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CAMK2N1 GENE; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LNCAP CELL LINE; LYMPH NODE METASTASIS; MALE; METASTASIS FREE SURVIVAL; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PGC GENE; PI3K AKT SIGNAL PATHWAY; PIP GENE; PLA2G16 GENE; PROMOTER REGION; PROSTATE CANCER; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; DNA RESPONSIVE ELEMENT; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETICS; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RESPONSE ELEMENTS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; ALPHAVIRUS; ALPHAVIRUS INFECTIONS; CELLS, CULTURED; CHIKUNGUNYA VIRUS; CRICETINAE; ENDOCYTOSIS; GENOME, HUMAN; HELA CELLS; HOST-PATHOGEN INTERACTIONS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; RNA, SMALL INTERFERING; SEMLIKI FOREST VIRUS; SINDBIS VIRUS; TRANSCRIPTOME; VIRUS INTERNALIZATION;

EID: 84903626213     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101411     Document Type: Article

References (46)

1. Surveillance, Epidemiology, and End Results Program site for the National Cancer Institute. Available: http://seer.cancer.gov/statfacts/html/prost.html. Accessed May 3, 2014.
2. Azzouni F, Mohler J (2012) Biology of castration-recurrent prostate cancer. Urol Clin North Am 39: 435-452.
3. Egan A, Dong Y, Zhang H, Qi Y, Balk SP, et al (2014) Castration-resistant prostate cancer: Adaptive responses in the androgen axis. Cancer Treat Rev 40: 426-433.
4. Sharifi N (2013) Mechanisms of androgen receptor activation in castration-resistant prostate cancer. Endocrinology 154: 4010-4017.
5. Yuan X, Cai C, Chen S, Chen S, Yu Z, et al. (2014) Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene 33: 2815-2825.
6. Bitting RL, Armstrong AJ (2013) Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer 20: R83-R99.
7. Sarker D, Reid AH, Yap TA, de Bono JS (2009) Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15: 4799-4805.
8. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
9. Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, et al (2013) Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res 73: 2718-2736.
10. Lin D, Gout PW, Wang Y (2013) Lessons from in-vivo models of castrationresistant prostate cancer. Curr Opin Urol 23: 214-219.
11. van der Vos KE, Coffer PJ (2011) The extending network of FOXO transcriptional target genes. Antioxid Redox Signal 14: 579-592.
12. Lam EW, Brosens JJ, Gomes AR, Koo CY (2013) Forkhead box proteins: tuning forks for transcriptional harmony. Nat Rev Cancer 13: 482-495.
13. Dong XY, Chen C, Sun X, Guo P, Vessella RL, et al (2006) FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res 66: 6998-7006.
14. Yang JY, Hung MC (2011) Deciphering the role of forkhead transcription factors in cancer therapy. Curr Drug Targets 12: 1284-1290.
15. Calnan DR, Brunet A (2008) The FoxO code. Oncogene 27: 2276-2288.
16. Shukla S, Bhaskaran N, Maclennan GT, Gupta S (2013) Deregulation of FoxO3a Accelerates Prostate Cancer Progression in TRAMP Mice. Prostate 73: 1507-1517.
17. Chen Q, Ganapathy S, Singh KP, Shankar S, Srivastava RK (2010) Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One 5: e15288.
18. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, et al (2007) Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity. Oncogene 26: 7647-7655.
19. van Duijn PW, Ziel-van der Made AC, van der Korput JA, Trapman J (2010) PTEN-mediated G1 cell-cycle arrest in LNCaP prostate cancer cells is associated with altered expression of cell-cycle regulators. Prostate 70: 135-146.
20. Zhang H, Pan Y, Zheng L, Choe C, Lindgren B, et al (2011) FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res 71: 3257-3267.
21. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, et al (2007) FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128: 309-323.
22. Eijkelenboom A, Mokry M, de WE, Smits LM, Polderman PE, et al (2013) Genome-wide analysis of FOXO3 mediated transcription regulation through RNA polymerase II profiling. Mol Syst Biol 9: 638.
23. Shin DJ, Joshi P, Hong SH, Mosure K, Shin DG, et al. (2012) Genome-wide analysis of FoxO1 binding in hepatic chromatin: Potential involvement of FoxO1 in linking retinoid signaling to hepatic gluconeogenesis. Nucleic Acids Res 40: 11499-11509.
24. Su B, Bu Y, Engelberg D, Gelman IH (2010) SSeCKS/Gravin/AKAP12 inhibits cancer cell invasiveness and chemotaxis by suppressing a PKC-RAF/MEK/ERK pathway. J Biol Chem 285: 4578-4586.
25. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, et al (2008) Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 68: 3323-3333.
26. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
27. Bu Y, Gao L, Gelman IH (2010) Role for transcription factor TFII-I in the suppression Of SSeCKS/Gravin/Akap12 transcription by Src. Int J Cancer 128: 1836-1842.
28. Baniwal SK, Little GH, Chimge NO, Frenkel B (2012) Runx2 controls a feedforward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation. J Cell Physiol 227: 2276-2282.
29. Langley RR, Fidler IJ (2011) The seed and soil hypothesis revisited - the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 128: 2527-2535.
30. Webber MM, Bello D, Quader S (1997) Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part 3. Oncogenes, suppressor genes, and applications. Prostate 30: 136-142.
31. Zhang Y, Gan B, Liu D, Paik JH (2011) FoxO family members in cancer. Cancer Biol Ther 12: 253-259.
32. Fu Z, Tindall DJ (2008) FOXOs, cancer and regulation of apoptosis. Oncogene 27: 2312-2319.
33. Lee MJ, Yu GR, Yoo HJ, Kim JH, Yoon BI, et al (2009) ANXA8 down-regulation by EGF-FOXO4 signaling is involved in cell scattering and tumor metastasis of cholangiocarcinoma. Gastroenterology 137: 1138-50, 1150.
34. Furuyama T, Nakazawa T, Nakano I, Mori N (2000) Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochem J 349: 629-634.
35. Baniwal SK, Little GH, Chimge NO, Frenkel B (2012) Runx2 controls a feed-forward loop between androgen and prolactin-induced protein (PIP) in stimulating T47D cell proliferation. J Cell Physiol 227: 2276-2282.
36. Little GH, Baniwal SK, Adisetiyo H, Groshen S, Chimge NO, et al (2014) Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness. Cancer Res 74: 2857-2868.
37. Blyth K, Vaillant F, Jenkins A, McDonald L, Pringle MA, et al (2010) Runx2 in normal tissues and cancer cells: A developing story. Blood Cells Mol Dis 45: 117-123.
38. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, et al (2010) Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29: 811-821.
39. Baniwal SK, Khalid O, Gabet Y, Shah RR, Purcell DJ, et al (2010) Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer 9: 258-259.
40. Yun SJ, Yoon HY, Bae SC, Lee OJ, Choi YH, et al (2012) Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer. Prostate Cancer Prostatic Dis 15: 369-373.
41. Thiolloy S, Rinker-Schaeffer CW (2011) Thinking outside the box: Using metastasis suppressors as molecular tools. Seminars In Cancer Biology 21: 89-98.
42. Little GH, Noushmehr H, Baniwal SK, Berman BP, Coetzee GA, et al. (2012) Genome-wide Runx2 occupancy in prostate cancer cells suggests a role in regulating secretion. Nucleic Acids Res 40: 3538-3547.
43. Benelli R, Monteghirfo S, Vene R, Tosetti F, Ferrari N (2010) The chemopreventive retinoid 4HPR impairs prostate cancer cell migration and invasion by interfering with FAK/AKT/GSK3beta pathway and beta-catenin stability. Mol Cancer 9: 142-149.
44. Bjerke GA, Yang CS, Frierson HF, Paschal BM, Wotton D (2013) Activation of Akt signaling in prostate induces a TGFbeta-mediated restraint on cancer progression and metastasis. Oncogene in press.
45. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, et al (2002) Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62: 4499-4506.
46. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, et al (2004) Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22: 2790-2799.